Drugs / Neihulizumab
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04144036 | Dec 2020 → Apr 2023 | acute graft versus host disease | Sameem M. Abedin, MD | Completed | No outcome recorded |
| Phase 1 | NCT03327857 | May 2018 → Sep 2022 | acute graft versus host disease | AltruBio Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02436460 | May 2015 → Mar 2016 | acute graft versus host disease | AbGenomics B.V Taiwan Branch | Terminated | No outcome recorded |
| Phase 1 | NCT01378364 | Jun → Nov 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02694770 | Jul 2016 → Sep 2017 | acute graft versus host disease | AbGenomics B.V Taiwan Branch | Withdrawn | No outcome recorded |
| Phase 2 | NCT02267642 | Jan → Oct 2015 | psoriatic arthritis | AbGenomics B.V Taiwan Branch | Completed | No outcome recorded |
| Phase 2 | NCT02223039 | May → Dec 2014 | psoriasis | AbGenomics B.V Taiwan Branch | Completed | No outcome recorded |
| Phase 2 | NCT01855880 | May 2013 → Feb 2014 | psoriasis | AbGenomics B.V Taiwan Branch | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neihulizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02694770 ↗ |
| Known as | AbGn-168H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02223039 ↗ |
| Known as | ALTB-168 | “Neihulizumab (ALTB-168) is an immune checkpoint agonist antibody that regulates T cell homeostasis.” NCT03327857 ↗ |
| Action | Deplete | “induces cell death preferentially in late-stage activated T cells” NCT03327857 ↗ |
| Action | Inhibit | “P-selectin glycoprotein ligand 1 inhibitor” CHEMBL4297861 ↗ |
| Modality | Monoclonal antibody | “AbGn-168H monoclonal antibody” NCT02223039 ↗ |
| Route | Intravenous | “single very low dose of AbGn-168H i.v.” NCT01378364 ↗ |
| Target | SELPLG | “P-selectin glycoprotein ligand 1 inhibitor” CHEMBL4297861 ↗ |